The tumor gDNA target sequencing (DEPArray OncoSeek panel, Menarini Silicon Biosystems) confirmed the FGFR2 amplification and reported the same frameshift variant in APC, even though with a lower allele frequency (p.T1556Nfs∗3, AF: 14%), likely due to contamination by normal cells. Here, FGFR2 is linked to neoplasm.